• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.

作者信息

Fumagalli Caterina, Guerini-Rocco Elena, Vacirca Davide, Passaro Antonio, Marinis Filippo de, Barberis Massimo

机构信息

Division of Pathology & Laboratory Medicine, European Institute of Oncology, Via Ripamonti 451, 20141 Milan, Italy.

Department of Oncology & Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.

出版信息

Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027.

DOI:10.2217/imt-2018-0027
PMID:30185137
Abstract
摘要

相似文献

1
The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在疾病初发时及酪氨酸激酶抑制剂治疗后的进展期的免疫特征
Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027.
2
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in Mutation-Positive Non-Small Cell Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂治疗对 EGFR 突变阳性非小细胞肺癌肿瘤免疫微环境的影响。
Clin Cancer Res. 2020 Apr 15;26(8):2037-2046. doi: 10.1158/1078-0432.CCR-19-2027. Epub 2020 Jan 14.
3
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.细胞毒化疗对 EGFR 突变和 ALK 融合阴性的非小细胞肺癌患者 PD-L1 表达的影响。
Lung Cancer. 2019 Jan;127:59-65. doi: 10.1016/j.lungcan.2018.11.025. Epub 2018 Nov 23.
4
Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.表皮生长因子受体酪氨酸激酶抑制剂原发性耐药的非小细胞肺癌的临床病理特征和免疫微环境。
Clin Lung Cancer. 2018 Jul;19(4):352-359.e1. doi: 10.1016/j.cllc.2018.02.004. Epub 2018 Feb 19.
5
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.肿瘤微环境对表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌疗效的影响。
Cancer Sci. 2019 Oct;110(10):3244-3254. doi: 10.1111/cas.14156. Epub 2019 Aug 30.
6
Tumor immune microenvironment of -mutant non-small-cell lung cancer and its impact on therapeutic efficacy.-突变型非小细胞肺癌的肿瘤免疫微环境及其对治疗疗效的影响。
Immunotherapy. 2020 May;12(7):431-437. doi: 10.2217/imt-2019-0213. Epub 2020 Apr 22.
7
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
8
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.表皮生长因子受体突变型非小细胞肺癌的免疫检查点抑制剂：当前的争议和未来的方向。
Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13.
9
Immunotherapy in non-small cell lung cancer harbouring driver mutations.携带驱动基因突变的非小细胞肺癌的免疫治疗
Cancer Treat Rev. 2021 May;96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub 2021 Mar 19.
10
Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma.一名转移性肺鳞状细胞癌患者中连续出现对EGFR酪氨酸激酶抑制剂的典型获得性耐药
J Oncol Pract. 2019 Feb;15(2):115-118. doi: 10.1200/JOP.18.00536.

引用本文的文献

1
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems.病理学家的PD-L1图谱：适应证、评分、诊断平台及报告系统
J Pers Med. 2022 Jun 29;12(7):1073. doi: 10.3390/jpm12071073.
2
A role for the immune system in advanced laryngeal cancer.免疫系统在晚期喉癌中的作用。
Sci Rep. 2020 Oct 27;10(1):18327. doi: 10.1038/s41598-020-73747-0.
3
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.免疫检查点抑制剂在表皮生长因子受体（EGFR）突变的非小细胞肺癌中的应用：从临床到实验室研究
Ther Adv Med Oncol. 2020 Jun 9;12:1758835920930333. doi: 10.1177/1758835920930333. eCollection 2020.